Skip to content
Research Article Open access CC BY 2.0

Downregulation of Gap Junctions in Astrocytes by Monoclonal Antibodies against the Second Extracellular Loop of Connexin-43

Vladimir P. Baklaushev, Nadezhda Ph. Grinenko, Eugene B. Tsitrin, Michael S. Belyaev, Vladimir E. Mukhin, Gaukhar M. Yusubalieva, Olga I. Gurina, Svetlana N. Bykovskaya, Vladimir P. Cheknonin

Journal of Advances in Medicine and Medical Research · pp. 35–44 · Published 14 Apr 2011

10.9734/BJMMR/2011/290

Abstract

Downregulation of gap junctions by monoclonal antibodies against the second extracellular loop of connexin-43 (E2Cx43) was studied in a passaged culture of astrocytes. The results of confocal laser scanning microscopy demonstrated that, after two hours of coincubation of cells loaded with Calcein AM and Dil according to Goldberg et al. and unlabelled cells, the cytoplasmic dye Calcein AM was actively transferred to unlabelled cells through newly formed gap junctions. This transfer could be almost completely blocked by addition of 60 μg/ml of anti-E2Cx43 antibodies. Flow cytometric analysis showed that, in experiments carried out according to Goldberg et al., with approximately 2% of labeled cells added to unlabelled ones, about 2.5% of the total cell population took up Calcein AM through gap junctions, thus forming a cell pool characterized by low-intensity green fluorescence. In the presence of antibodies, the proportion of these cells was no more than 0.6%, which indicates an at least fourfold suppression of the gap junction function by E2Cx43 antibodies. The data obtained were reproduced in several independent series. Thus, we obtained monoclonal antibodies capable of modulating the gap junction function in cultures of Cx43-positive cells.

Gap-junction connexin-43 extracellular loop monoclonal antibodies

References (19)

  1. 1 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [DOI]
  2. 2 Applied Logistic Regression Analysis [DOI]
  3. 3 Diagnosis, management, and treatment of hepatitis C: An update # † ‡ [DOI]
  4. 4 Diagnosis, management, and treatment of hepatitis C† [DOI]
  5. 5 Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3☆ [DOI]
  6. 6 Management of hepatitis C [DOI]
  7. 7 Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2 [DOI]
  8. 8 Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors [DOI]
  9. 9 A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C [DOI]
  10. 10 PSG consensus statement on management of hepatitis C virus infection--2003.
  11. 11 Management of hepatitis.
  12. 12 Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients [DOI]
  13. 13 Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response.
  14. 14 Response rates to standard interferon treatment in HCV genotype 3a.
  15. 15 Factors influencing the response of interferon therapy in chronic hepatitis C patients.
  16. 16 Expression of liver steatosis in hepatitis C virus infection and pattern of response to α-interferon [DOI]
  17. 17 Interferon and Ribavirin for Patients With Chronic Hepatitis C Who Did Not Respond to Previous Interferon Therapy: A Meta–Analysis of Controlled and Uncontrolled Trials [DOI]
  18. 18 Nucleotide identity and variability among different Pakistani hepatitis C virus isolates [DOI]
  19. 19 Obesity and Its Nurturing Effect on Hepatitis C [DOI]

Cited by 3

A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges

Muhammad Ali, Samia Afzal, Asad Zia · Medicine · 2016

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

29

Page views

0

PDF downloads

3

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.